Status:
COMPLETED
BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
Lead Sponsor:
Braintree Laboratories
Conditions:
Acne Vulgaris
Eligibility:
All Genders
12-45 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare the safety and efficacy of formulation BLI1100 to its vehicle in the treatment of moderate-severe acne vulgaris.
Eligibility Criteria
Inclusion
- Qualifying Investigator's Global Assessment severity score
- Qualifying number of non-inflammatory lesions
- Qualifying number of inflammatory lesions
Exclusion
- Facial hair (beard), excessive scarring, sunburn or other disfigurement that may obscure the accurate assessment of acne grade
- Using medications that are reported to exacerbate acne
- Any clinically relevant finding at their baseline physical examination or dermatological medical history such as severe systemic diseases or diseases of the facial skin
- Have a known hypersensitivity or previous allergic reaction to any of the components
- Patients who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
- Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT01241331
Start Date
November 1 2010
Last Update
October 1 2012
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Dermatology Clincal Research
Fremont, California, United States, 94538
2
Dermatology Research Associates
Los Angeles, California, United States, 90045
3
Dermatology Specialists
Oceanside, California, United States, 92056
4
Horizons Clinical Research Center
Denver, Colorado, United States, 80220